VISCHER has advised TargImmune on the deal. TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused...
VISCHER has advised TargImmune on the deal. TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused...
You must be a Standard 1 Year member to access this content.